3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Breast Neoplasms
327
Neoplasm Metastasis
31
Advanced Breast Cancer
19
Neoplasms
17
Ovarian Neoplasms
11
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
7
Endometrial Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Breast Diseases
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms by Site
4
Colorectal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Recurrence
3
Multiple Endocrine Neoplasia Type 1
3
Head and Neck Neoplasms
3
Breast Neoplasm Female
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Liposarcoma
2
Hyperglycemia
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Breast Cancer
2
Interventions
Alpelisib
3
Fulvestrant
2
volagidemab
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Metformin
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Fulvestrant
×
Breast
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts